In Vivo Biocompatibility of ZIF-8 for Antigen Slow Release via Intranasal Administration
S. Kumari, T. S. Howlett, R. N. Ehrman, S. Koirala, O. Trashi, I. Trashi, Y. H. Wijesundara, J. J. Gassensmith
This study evaluates the in vivo biocompatibility of ZIF-8 for antigen slow release via intranasal administration, finding no significant adverse effects on blood serum proteins, lung function, or tissue morphology.
bioRxiv · Jan 7, 2023 · PreprintPharmacology & Toxicology